Korro Bio grants stock options to new hires
Analysis based on 6 articles · First reported Jul 10, 2026 · Last updated Jul 10, 2026
This is a routine corporate action with minimal market impact. It reflects standard hiring practices for a biopharmaceutical company.
Korro Bio, Inc. (Nasdaq: KRRO) announced the grant of non-statutory stock options to seven newly hired employees as an inducement material to their acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options were granted under Korro's 2026 Inducement Plan, with four employees receiving options to purchase 6,000 shares at $10.59 per share and three employees receiving options to purchase 17,000 shares at $14.72 per share. The options have a ten-year term and vest over four years.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard